BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).
We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma, said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell. Our NK cells elicited an adaptive immune response in patients in the previous investigator-sponsored study with the fresh formulation of GDA-201, potentially leading to durable remissions. We are truly grateful for the contribution of all the participants and clinical collaborators who will allow us to continue studying GDA-201 in this multi-center open label trial.
The Phase 1 portion of the study is a dose escalation phase, designed to evaluate the safety of GDA-201, and will include patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma, marginal zone lymphoma or mantle cell lymphoma. The Phase 2 expansion phase is designed to evaluate the safety and efficacy of GDA-201 in 63 patients comprised of two cohorts of patients with either FL or DLBCL. The study will include patients who have relapsed or refractory lymphoma after at least two prior treatments, which may include CAR-T or stem cell transplant.
Interest in NK cell therapies has increased in recent years as a potential alternative to current cell therapies, as NK cells have the potential to be effective in hematological and solid tumors while avoiding common safety issues, said Veronika Bachanova, M.D., Ph.D., University of Minnesota. We are particularly excited about Gamidas cryopreserved formulation of GDA-201, which has potential as a new treatment option for patients.
GDA-201 leverages Gamida Cells proprietary NAM (nicotinamide) technology platform to expand the number and functionality of NK cells to direct tumor cell killing properties and antibody-dependent cellular cytotoxicity (ADCC). In an investigator-sponsored Phase 1/2 study in patients with relapsed or refractory lymphoma, treatment with the fresh formulation of GDA-201 with rituximab demonstrated significant clinical activity. Of the 19 patients with non-Hodgkin lymphoma (NHL), 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate of 68%. Two-year data on outcomes and cytokine biomarkers associated with survival data demonstrated a median duration of response of 16 months (range 5-36 months) and an overall survival at two years of 78% (95% CI, 51%91%). In this study, GDA-201 was well-tolerated and no dose-limiting toxicities were observed in 19 patients with NHL and 16 patients with multiple myeloma. The most common Grade 3/4 adverse events were thrombocytopenia, hypertension, neutropenia, febrile neutropenia, and anemia. There were no incidents of cytokine release syndrome, neurotoxic events, graft versus host disease or marrow aplasia.
About NAM Technology
Our NAM-enabled technology, supported by positive Phase 3 data for omidubicel, is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. Leveraging the unique properties of NAM, we can expand and metabolically modulate multiple cell types including stem cells and NK cells with appropriate growth factors to maintain the cells active phenotype and enhance potency. Additionally, our NAM technology improves the metabolic fitness of cells, allowing for continued activity throughout the expansion process.
About GDA-201
Gamida Cell applied the capabilities of its NAM-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy candidate for the treatment of hematologic and solid tumors in combination with standard-of-care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, GDA-201 improves ADCC and tumor targeting of NK cells. There are approximately 40,000 patients with relapsed/refractory lymphoma in the US and EU, which is the patient population that will be studied in the currently ongoing GDA-201 Phase 1/2 clinical trial.
For more information about GDA-201, please visit https://www.gamida-cell.com. For more information on the Phase 1/2 clinical trial of GDA-201, please visit http://www.clinicaltrials.gov.
GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.
About Gamida Cell
Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit http://www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to: the timing of initiation of the expansion portion of the currently ongoing Phase 1/2 clinical trial of GDA-201, as well as the progress of, and data reported from, this clinical trial; the potentially life-saving or curative therapeutic and commercial potential of Gamida Cells product candidates (including omidubicel and GDA-201); and Gamida Cells expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cells goals, expectations, or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including statements related to: the impact that the COVID-19 pandemic could have on our business; the scope, progress and expansion of Gamida Cells clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics; and the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cells Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on May 12, 2022, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cells actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.
Follow this link:
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 - Business Wire
- Stem cell treatment after spinal cord injury: The next steps - Mayo Clinic - December 18th, 2022
- A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage - The Scientist - October 13th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 13th, 2022
- A history of blood cancer treatment - - pharmaphorum - September 16th, 2022
- What Are Zombie Cells? Here's How They Impact Aging - Prevention Magazine - September 8th, 2022
- ThreeSixty Journalism: Be The Match works to build equity in access to bone marrow and cord blood transplants - St. Paul Pioneer Press - September 8th, 2022
- Zhang and colleagues win an $11.2 million NIH program project grant (PPG) - News - University of Alabama at Birmingham - August 22nd, 2022
- Kyle Vining: Appointment to Faculty of Penn Dental Medicine and Penn School of Engineering and Applied Science - University of Pennsylvania - August 22nd, 2022
- Engineers develop new tool that will allow for more personalized cell therapies - UMN News - July 27th, 2022
- University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune - July 27th, 2022
- Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes - UCSF - July 27th, 2022
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 11th, 2022
- Witt Wolfpack: Family works out fundraising and awareness after La Jollan's ALS diagnosis - La Jolla Light - July 11th, 2022
- Pluripotent stem cellderived NK cells with high-affinity noncleavable ... - July 3rd, 2022
- Life-saving lecture: Auburn student uses lessons from class to help discover father's brain tumor - Office of Communications and Marketing - June 22nd, 2022
- Bluebird's future in balance as FDA weighs gene therapy approvals - BioPharma Dive - June 13th, 2022
- Be the Match is looking for more ethnically diverse donors to help patients with blood cancers and diseases - KARE11.com - June 4th, 2022
- Minnesota woman reunites with teenager she saved through Be The Match transplant - KSTP - April 19th, 2022
- Induced Pluripotent Stem Cells and Their Potential for ... - November 22nd, 2021
- Cells or drugs? The race to regenerate the heart - Scientific American - November 8th, 2021
- Four-year-old with rare disease finally gets historic gene therapy treatment - KARE11.com - October 5th, 2021
- Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors - Stockhouse - October 5th, 2021
- EDITORIAL: The need is vast. Consider becoming an organ donor. - Yahoo News - August 18th, 2021
- Our View: The need is vast. Consider becoming an organ donor. - PostBulletin.com - August 18th, 2021
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 11th, 2020
- COVID-19 and the trials of treatment | News, Sports, Jobs - Escanaba Daily Press - October 16th, 2020
- NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - Watauga Democrat - October 7th, 2020
- Berks County's first STEM-themed attraction opens, delights visitors young and old - Reading Eagle - October 7th, 2020
- Coronavirus Thursday update: UMN announces new stem cell ... - August 16th, 2020
- University of Minnesota launches stem cell trial against ... - August 16th, 2020
- University of Minnesota launches stem cell trial against severe COVID-19 - Minneapolis Star Tribune - August 16th, 2020
- Biotechnology Could Change the Cattle Industry. Will It Succeed? - Singularity Hub - August 16th, 2020
- Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update - Yahoo Finance - April 4th, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 4th, 2020
- Coronavirus is similar to SARS and causes infection through a heart regulating enzyme: Study - International Business Times, Singapore Edition - February 4th, 2020
- Why Sangamo Therapeutics Stock Sank Today - The Motley Fool - December 13th, 2019
- Hoeven's bill supports alternative therapy for veterans with PTSD, traumatic brain injury - Ripon Advance - October 1st, 2019
- Stem-cell treatment gives two brothers a future ... - March 3rd, 2019
- The Promise of Stem Cells | Stem Cell Institute ... - August 29th, 2018
- 2018 Regenerative Medicine Minnesota Research Awards - August 17th, 2018
- FDA cracks down on stem cell clinics - CNN - August 29th, 2017
- Mayo Clinic, University of Minnesota develop 'robocop' stem cells to fight cancer - Minneapolis Star Tribune - August 24th, 2017
- Cowboy Up Ride Against Cancer - Wahpeton Daily News - August 24th, 2017
- Cargill invests in 'clean meat' start-up - KARE - August 24th, 2017
- Stem-cell clinics are using a federal website as a marketing tool for unproven treatments, U of M bioethicist says - MinnPost - July 30th, 2017
- More than 60 US clinics have sold unproven stem cell therapies for heart failure - New York Post - July 30th, 2017
- Stemonix, a stem cell research firm, wins Minnesota Cup ... - November 27th, 2016
- Minnesotas Funding of Stem Cell Research Echoes Trend ... - October 29th, 2016
- Stem cell research Experts@Minnesota - October 18th, 2016
- Stem Cell FAQs - Minnesota Regenerative Medicine - October 7th, 2016
- Minnesota invests in regenerative medicine - Health Talk - October 7th, 2016
- Minnesota to resume umbilical cord blood donations ... - September 20th, 2016
- STEM Programs - Minnesota Zoo - September 5th, 2016
- Stem Cell Treatment - Minnesota Regenerative Medicine - August 18th, 2016
- Home - Minnesota Regenerative Medicine - August 18th, 2016
- Multipotent vs. pluripotent stem cells - Pathology Student - October 19th, 2015
- 2. Bone Marrow (Hematopoietic) Stem Cells [Stem Cell ... - October 19th, 2015
- Minnesota Man With ALS Hopes Stem Cells Save His Life ... - July 2nd, 2015
- Graduate Programs - MED - Stem Cell Institute, University ... - April 26th, 2015
- Atsushi Asakura, Ph.D. - MED - Stem Cell Institute ... - March 18th, 2015
- Bioelectricity Plays Key Role in Brain Development & Repair - March 13th, 2015
- Jakub Tolar, M.D., Ph.D. - MED - Stem Cell Institute ... - February 24th, 2015
- Stem Cell Web Focus - Nature Publishing Group : science ... - February 3rd, 2015
- Family: Experimental stem-cell treatment does wonders for Gordie Howe - December 20th, 2014
- Childrens hospital gets $25M - December 16th, 2014
- Stem Cell Malaysia Blog - December 12th, 2014
- Reduction of germ cells yields more zebrafish males - December 4th, 2014
- Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical ... - November 28th, 2014
- Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer - November 10th, 2014
- Anti-Cancer Drug Effective Against Common Stem Cell Transplant Complication - October 24th, 2014
- $25M gift prompts University pediatric hospital name change - October 16th, 2014
- Becoming a blood stem cell or bone marrow donor ... - October 3rd, 2014
- New heart built with stem cells - YouTube - September 27th, 2014
- Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial - September 12th, 2014
- Researchers find animal model for understudied type of muscular dystrophy - August 30th, 2014
- Minnesota Stem Cell Therapy | Stem Cell Treatments - August 29th, 2014
- Stem Cell FAQs - MED - Stem Cell Institute, University of ... - August 22nd, 2014
- Home - MED - Stem Cell Institute, University of Minnesota - August 22nd, 2014
- Stem cells | Health Sciences - University of Minnesota - August 22nd, 2014